SCHEMBL16396240

SCHEMBL16396240

COC(=O)c1cc2cc(NS(C)(=O)=O)c(Cl)cc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
MAPK14 Q16539 1/20 0.43
PTPN2 P17706 1/20 0.42
MCL1 Q07820 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
STING1 Q86WV6 5/20 0.41
HDAC1 Q13547 2/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
CTPS1 P17812 1/20 0.38
CLK1 P49759 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16395989 0.95 MEN1 (0.46) MEN1KMT2AMAPTMAPK14PTPN2
SCHEMBL16396080 0.89 GPR35 (0.46) MAPK14PTPN2MCL1STING1
SCHEMBL19433555 0.85 MAPT (0.46) MEN1KMT2AMAPTMAPK14PTPN2
SCHEMBL16395990 0.84 MAPT (0.46) MEN1KMT2AMAPTMAPK14PTPN2
SCHEMBL16396068 0.84 PTPN2 (0.50) MEN1KMT2AMAPTMAPK14PTPN2
SCHEMBL16395961 0.84 STING1 (0.51) MEN1KMT2AMAPTMAPK14PTPN2
SCHEMBL16396067 0.84 GPR35 (0.46) MAPK14PTPN2MCL1STING1
SCHEMBL17842816 0.81 STING1 (0.52) MEN1KMT2AMAPTPTPN2KDM4E
SCHEMBL19433283 0.80 PTPN2 (0.45) MEN1KMT2AMAPTPTPN2MCL1
SCHEMBL19433734 0.78 MAPK14 (0.43) MEN1KMT2AMAPTMAPK14PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A MEN1 3206/4885KMT2A 3017/4885MAPT 4514/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A MEN1 3206/4885KMT2A 3017/4885MAPT 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.